Pralatrexate

T-Cell Non-Hodgkin Lymphoma

Fred Hutchinson Cancer CenterSmall moleculePhase 3Active

BB

64/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 56/ 100
Competitive Position: 81/ 100

Competitive context

83 Active assets in the T-Cell Non-Hodgkin Lymphoma cohort.

Asset / Sponsor	Phase	Rating
Fludarabine GC Cell Corporation	Phase 2	BBB
Brentuximab Vedotin Yale University	Phase 4	BBB
Rituximab Memorial Sloan Kettering Cancer Center	Phase 2	BB
Cyclophosphamide GC Cell Corporation	Phase 3	BB
Lenalidomide Samsung Medical Center	Phase 2	BB

View all 50 →

Same molecule, other indications

Pralatrexate is also rated in:

peripheral T-cell lymphoma, not otherwise specifiedActive

BBB

Indicative · Phase 4

74 / 100

angioimmunoblastic T-cell lymphomaActive

BB

Indicative · Phase 3

66 / 100

Nodal T-follicular helper cell lymphoma, follicular typeActive

BB

Indicative · Phase 3

64 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.